EN
Clinical Features And Follow-Up Results Of Children With Hyperthroidism
Abstract
Objective: Hyperthyroidism is a rare clinical condition in childhood that can cause serious problems. Information on the epidemiological features, follow-up and treatment of pediatric patients with hyperthyroidism is quite limited. In this study, clinical and laboratory findings and follow-up results of children with hyperthyroidism are presented.
Materials and Methods: The data of children with hyperthyroidism between 2005-2022 at Atatürk University and Erzurum Health Sciences University Pediatric Endocrinology clinics were retrospectively analyzed.
Results: 43 (81.1%) female and 10 (18.9%) male patients aged 2-18 years (14.05±3.0) were included in the study. Of the patients, 36 (67.9%) had Graves' disease (GD), 14 (26.4%) had Hashimoto's thyroiditis (HT), 2 (3.8%) had subacute thyroiditis, and 1 (1.9%) had hyperactive thyroid nodules. The most common symptoms were palpitations (75.5%), sweating (60.4%), tremors in the hands (49.1%), heat intolerance (45.3%) and weight loss (32.1%). Mean SD values of height, body weight and body mass index at the time of diagnosis were -0.05±1.16, -0.67±1.20 and -0.77±1.25, respectively. Goitre and exophthalmos were present in 69.8% and 30.2% of the cases, respectively. At the time of diagnosis, mean serum thyroid stimulating hormone (TSH), free tri-iodothyronine, free tetra-iodothyronine, thyroglobulin, anti-thyroid peroxidase, anti-thyroglobulin and TSH receptor antibody levels were 0.03±0.09 mIU/L, 13.0.34±7.07 pg/ml, 3.30±1.70 ng/dl, 101.93±180.35 ng/ml, 600.30±858.58 IU/ml, 322.82±644.08 IU/ml, and 12.41 ±14.37 IU/L, respectively. 42 (79.2%) patients were treated with propranolol and methimazole, 3 (5.7%) patients were treated with propranolol and propylthiouracil, and 4 (7.5%) patients were treated with propranolol, while 4 (7.5%) patients were untreated. The mean duration of treatment was 14.67±17.51 months. The mean time to euthyroid state antithyroid drug (ATD) was 24.80±14.33 days. While no serious drug-related side effects were detected in any patient, urticaria rash developed in 1 (1.9%) patient in the 1st month of treatment. Total thyroidectomy was performed in 3 cases with GD and 1 case with hyperactive thyroid nodules. Radioactive iodine treatment was not given to any of the cases. The remission rate in patients with GD was 46.7% at the early stage of treatment and 16.7% during the entire follow-up. The recurrence rate was 71.4%. At the last visit, 15 (28.3%) patients were euthyroid, 1 (1.9%) hyperthyroid, and 5 (9.4%) hypothyroid. While 21 (39.6%) of the cases were still using antithyroid medication, 11 (20.8%) were excluded from follow-up.
Conclusion: The first and second most common causes of hyperthyroidism in children and adolescents are GH and HT, respectively. TRAb positivity, thyroid scintigraphy findings and clinical follow-up may be useful in distinguishing between GH and HT. ATD therapy is effective and safe in keeping GH in remission.
Materials and Methods: The data of children with hyperthyroidism between 2005-2022 at Atatürk University and Erzurum Health Sciences University Pediatric Endocrinology clinics were retrospectively analyzed.
Results: 43 (81.1%) female and 10 (18.9%) male patients aged 2-18 years (14.05±3.0) were included in the study. Of the patients, 36 (67.9%) had Graves' disease (GD), 14 (26.4%) had Hashimoto's thyroiditis (HT), 2 (3.8%) had subacute thyroiditis, and 1 (1.9%) had hyperactive thyroid nodules. The most common symptoms were palpitations (75.5%), sweating (60.4%), tremors in the hands (49.1%), heat intolerance (45.3%) and weight loss (32.1%). Mean SD values of height, body weight and body mass index at the time of diagnosis were -0.05±1.16, -0.67±1.20 and -0.77±1.25, respectively. Goitre and exophthalmos were present in 69.8% and 30.2% of the cases, respectively. At the time of diagnosis, mean serum thyroid stimulating hormone (TSH), free tri-iodothyronine, free tetra-iodothyronine, thyroglobulin, anti-thyroid peroxidase, anti-thyroglobulin and TSH receptor antibody levels were 0.03±0.09 mIU/L, 13.0.34±7.07 pg/ml, 3.30±1.70 ng/dl, 101.93±180.35 ng/ml, 600.30±858.58 IU/ml, 322.82±644.08 IU/ml, and 12.41 ±14.37 IU/L, respectively. 42 (79.2%) patients were treated with propranolol and methimazole, 3 (5.7%) patients were treated with propranolol and propylthiouracil, and 4 (7.5%) patients were treated with propranolol, while 4 (7.5%) patients were untreated. The mean duration of treatment was 14.67±17.51 months. The mean time to euthyroid state antithyroid drug (ATD) was 24.80±14.33 days. While no serious drug-related side effects were detected in any patient, urticaria rash developed in 1 (1.9%) patient in the 1st month of treatment. Total thyroidectomy was performed in 3 cases with GD and 1 case with hyperactive thyroid nodules. Radioactive iodine treatment was not given to any of the cases. The remission rate in patients with GD was 46.7% at the early stage of treatment and 16.7% during the entire follow-up. The recurrence rate was 71.4%. At the last visit, 15 (28.3%) patients were euthyroid, 1 (1.9%) hyperthyroid, and 5 (9.4%) hypothyroid. While 21 (39.6%) of the cases were still using antithyroid medication, 11 (20.8%) were excluded from follow-up.
Conclusion: The first and second most common causes of hyperthyroidism in children and adolescents are GH and HT, respectively. TRAb positivity, thyroid scintigraphy findings and clinical follow-up may be useful in distinguishing between GH and HT. ATD therapy is effective and safe in keeping GH in remission.
Keywords
References
- KAYNAKLAR 1-Léger J, Carel JC. Diagnosis and management of hyperthyroidism from prenatal life to adolescence. Best Pract Res Clin Endocrinol Metab. 2018 Aug;32(4):373-86
- 2-Léger J, Carel JC. Hyperthyroidism in childhood: causes, when and how to treat. J Clin Res Pediatr Endocrinol. 2013;5 Suppl 1(Suppl 1):50-6.
- 3-Binay Ç, Şimşek E. Çocuk ve Adolesanlarda Hashimoto Tiroiditi. Osmangazi Tıp Dergisi/Osmangazi Journal of Medicine, Mayıs/May, 2016;38 (2), 1-8
- 4-Radetti G. Clinical aspects of Hashimoto's thyroiditis. Endocr Dev. 2014;26:158-70
- 5-Król A, Czarniecka A, Jarząb B. Definitive treatment of Graves' disease in children and adolescents. Endokrynol Pol. 2021;72(6):661-5
- 6-Esen İ, Bayramoglu E, Yıldız M et al. Management of Thyrotoxicosis in Children and Adolescents: A Turkish Multi-center Experience. J Clin Res Pediatr Endocrinol 2019;11(2):164- 72
- 7-Işık E, Alikaşifoğlu A. Çocuk ve Adölesan Yaş Grubundaki Hipertiroidili Olguların Değerlendirilmesi ve Uzun Süreli İzlemi. Ankara 2013. (https://tez.yok.gov.tr/UlusalTezMerkezi/tezSorguSonucYeni.jsp).
- 8-Demir K, Konakçı E, Özkaya G et al. New features for Child Metrics: Further growth references and blood pressure calculations. J Clin Res Pediatr Endocrinol. 2020;12(2):125-9.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Publication Date
October 1, 2022
Submission Date
May 11, 2022
Acceptance Date
September 28, 2022
Published in Issue
Year 2022 Volume: 44 Number: 3